Global
Global Home
|
CSL Behring US
|
CSL Plasma
|
All CSL Behring Web Sites
All Sites
Choose country
Argentina
Australia
Austria
Belgium/Luxembourg
Brazil
Canada
China
Czech Republic
Denmark
France
Germany
Greece
Italy
Japan
Mexico
Netherlands
Nordic
Spain
Switzerland
UK
USA
CSL Plasma US
CSL Plasma Germany
Home
About CSL Behring
Products
Patient Commitment
Environment, Health, Safety & Sustainability
Quality & Safety
CSL Research & Development
Clinical Trials
Other Areas of Business
Partners
News Room
Careers
Contact Us
Home
> Home
Product Overview
CSL Behring develops, manufactures and markets protein based therapies, including:
Bleeding Disorders Therapies
Fluid Replacement Therapies
Hereditary Angioedema (HAE) Therapies
Immunoglobulin Therapies
Pulmonary Therapies
Wound Healing Therapies
Global Product Portfolio
Features
Going to School With Hemophilia
Five ways to help your child.
New on BioBlog
Yesli Paillacán faced many challenges growing up with a primary immunodeficiency in Chile
Paul Perreault on Being Passionate and Direct
Read his remarks in the Australian Financial Review about managing CSL into the future.
News
25-July-2017
HAEGARDA now available to HAE patients in the US
21-July-2017
FDA Grants Orphan-Exclusivity to HAE treatment
19-July-2017
FDA Accepts sBLA for CIDP indication
12-July-2017
IDELVION
®
Data Presented at ISTH 2017
11-July-2017
CSL Behring Awards Immunoglobulin Research Grants
View all news
Share
More Options
